Contraceptive Drugs and Devices Market: Current Analysis and Forecast (2021-2027)

Contraception is the use of agents, drugs, devices, surgical procedures, for the prevention of unwanted pregnancy. Various Devices, along with treatments, are available for both women and men. The effectiveness of the method depends on how carefully a method has been used. For instance, the use of the contraceptive pill is a 99% efficient method but still 9 women every year become pregnant while using this method. The demand for Contraceptive drugs and devices is increasing on account of the necessity for the prevention of rising rates of unintended pregnancies and increasing consciousness amongst people regarding contraceptive pills. However, some of the restraints in the market include the side effects associated with the use of contraceptive drugs and the high cost of devices and treatments. In 2019, of the 1.9 billion women of reproductive age (15-49 years) living in the world, 1.1 billion needed family planning, they are either current users of contraceptives, 842 million use modern methods of contraception and 80 million use traditional methods or have an unmet need for family planning. 190 million women want to avoid pregnancy and do not use any contraceptive method.

Based on Products, the market is segmented into drugs and devices. The drugs segment is further bifurcated into Oral Contraceptives, Topical Contraceptives and Contraceptive Injectable. The devices segment is bifurcated into Condoms, Diaphragms, Cervical Caps, Sponges Vaginal Rings, and IUD. Within the Contraceptive drugs and device market, oral contraceptives hold the major share due to the following reasons Oral Contraceptive pills are 99% effective for the prevention of pregnancy; hence it is widely used by women; Easy to intake; Easily available as over-the-counter oral contraceptives and Inexpensive. The oral Contraceptives segment generated revenue of USD XX million in 2020. The market is expected to grow at a CAGR of XX% during the forecast period to reach a market valuation of USD XX million by 2027F. In terms of Devices, condoms are mainly used owing to increase cases of unwanted pregnancies, increase cases of STDs, and an increasing government initiative to tackle increasing population.

Based on Gender, the market is divided into Male and Female. The Male subsegment grabbed the major market owing to the increase in commercialization of male birth control Devices such as contraceptive injection for men. The Male sub-segment generated revenue of USD XX million in 2020. The female subsegment grabbed the major market owing to an increase in unwanted pregnancies and government initiatives. The Female sub-segment generated revenue of USD XX million in 2020. Based on the distribution channel, the market is segmented into Hospital & Clinics, Retail Pharmacy, Online Pharmacy, and Others. The retail pharmacy is expected to be the fastest-growing market owing to an increase in over-the-counter purchasing of contraceptive drugs.

For a better understanding of the market adoption, the market is analyzed based on its worldwide adoption in countries such as North America (US, Canada, and Rest of North America), Europe (Germany, France, Italy, Spain, UK, and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, and Rest of APAC), and Rest of World. North America constitutes a major market for the Contraceptive Drugs and Devices industry, with revenue share of XX% in 2020. The global Contraceptive Drugs and Devices Market was valued at USD XX million in 2020 and is projected to expand significantly with a CAGR of XX% from 2021F to 2027F. The global Contraceptive Drugs and Devices Market is expected to witness a boost on account of the necessity for the prevention of rising rates of unintended pregnancies and increasing consciousness amongst people regarding contraceptive pills.

Some of the major players operating in the market include Bayer AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Mylan N.V., Allergan Plc, Agile Therapeutics, Piramal Enterprises Ltd., GlaxoSmithKline PLC, Johnson & Johnson, Novartis AG, and Sanofi etc. Several M&A's along with partnerships have been undertaken by these players to boost their presence in different regions.